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ABSTRACT

Nicotine sensitization in a rodent model of schizophrenia:
A comparison of adolescents, adults, and neurotrophic factors
by
Marla K. Perna
The behavioral effects of nicotine on locomotor activity in a rodent model of psychosis were
analyzed. This model is based on neonatal quinpriole treatment (a dopamine D2/D3 agonist)
which causes increased D2 receptor sensitivity, a phenomenon known as D2 priming that is
common in schizophrenia. D2-primed adolescent rats did not demonstrate nicotine-induced
hypoactivity early in training, and males demonstrated more rapid sensitization to nicotine as
compared to controls administered nicotine. D2-primed females administered nicotine
demonstrated increased stereotypic behavior. D2-primed adult rats given nicotine demonstrated
significantly more robust sensitization to nicotine than controls given nicotine. Brain-derived
neurotrophic factor (BDNF) was analyzed in the nucleus accumbens. BDNF was significantly
increased in nicotine treated adolescent females but was not affected in males. Nicotine
alleviated BDNF deficits in D2-primed adults. These results suggest that sensitization to nicotine
in D2-primed rats is age dependent, and nicotine induced changes in BDNF that is age and sexdependent.
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CHAPTER 1
INTRODUCTION
Schizophrenia is a debilitating disorder that affects approximately 1% of the population.
The symptoms of schizophrenia involve a combination of positive and negative symptoms
accompanied by impairment in social and/or occupational function according to the DSM-IV-TR
(2000). Positive symptoms may be described as a loss of contact with reality, delusions,
hallucinations, and bizarre behaviors. Hallucinations include auditory, visual, tactile, and
olfactory hallucinations. The most common hallucinations are auditory, including hearing voices
and sounds that are not shared by others (American Psychiatric Association Diagnostic and
Statistical Manual, 2000; Mueser & McGurk, 2004 ). Negative symptoms of the disease include
flattened affect (lack of emotion, monotonous voice tone, and immobile facial expression),
anhedonia (the absence of pleasure and the inability or lack of motivation to follow through on
plans), low goal-oriented behavior, and alogia (a reduced amount of speech or content of
conversation). The DSM-IV-TR further lists impairment of social and occupational functions
that include an inability to retain social relationships in personal and professional settings, as
well as an inability to care for oneself.
Psychostimulant Abuse in Schizophrenia
Research has shown a significantly higher incidence of drug abuse in schizophrenics as
compared to the general population, (Cuffel, 1992; LeDuc & Mittleman, 1993), and the
incidence of drug abuse in schizophrenics has been steadily increasing in recent years. In 1965,
4.5% of schizophrenics reported use of psychostimulants. In 1990, 25.3% reported use of
psychostimulants (Cuffel), and by 1999, 50% reported use of psychostimulants. Among
psychostimulants, nicotine is used most often. Approximately 90% of the schizophrenic
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population smokes cigarettes as compared to only 20% of the general population (Levin, Wilson,
Rose, & McEvoy, 1996). Recent research suggests that schizophrenics may be using nicotine to
self-medicate or to possibly relieve the unpleasant side effects of prescribed medications.
(Friedman, Adler, & Davis, 1999; Leonard & Giordano. 2002)
Dopamine Dysfunction in Schizophrenia
Increased dopamine (DA) activity has been found in several psychiatric disorders
including obsessive-compulsive disorder, attention-deficit hyperactive disorder, bipolar disorder,
and schizophrenia. Research has shown that increased dopamine function is a key element in the
etiology of schizophrenia. For example, dopaminergic receptors have been shown to have an
increased sensitivity in schizophrenia (Kegeles et al., 2000) and all antipsychotic drugs used to
treat schizophrenia block dopamine D2 receptors with some affinity (Tollefson, 1994). Research
has shown that increased DA function in the prefrontal cortex and the nucleus accumbens may
be involved in positive symptomology of the disease (Drew, Derbez, & Werling, 2000).
Therefore, it appears that the dopamine neurotransmitter system is hyperactive in schizophrenia.
Dopamine Function in the Brain.
Dopaminergic cell bodies are primarily located in the ventral tegmental area (VTA) and
project to several different brain areas including the basal ganglia, nucleus accumbens, with less
major projections to the olfactory tubercle, hippocampus, and cerebral cortex. An important
dopamine projection that plays a major role in positive reinforcement and drug addiction
originates from DA cell bodies in the VTA and projects to the nucleus accumbens and frontal
cortex. The projection from the VTA to the nucleus accumbens (Nacc) has been hypothesized to
be the primary drug reinforcement pathway in the brain and is referred to as the mesolimbic
dopamine pathway. Blockade of dopamine receptors either in the VTA or Nacc blocks self-
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administration of reinforcing drugs such as nicotine, cocaine, and amphetamine (Adinoff, 2004;
Badanich & Kirsteina, 2004; Maldonado, 2003), and dopamine receptor blockade also alleviates
locomotor sensitization to drugs known to activate this pathway (Hsu, Tsou, Chiu, & Chau,
2005; Pierre & Vezina, 1998; Pudiak & Bozarth, 1997). Additionally, animals will work for
stimulation of this brain pathway via an electrode that is activated by a lever press from the
animal (Suto et al., 2003; Suto, Tanabe, Austin, Creekmore, & Vezina, 2002). Thus, it is
apparent that the mesolimbic dopamine pathway is involved in mediating reinforcing effects of
stimuli.
Drug Abuse Mechanisms in the Brain
The two main theories of addiction focus on dopamine depletion and sensitization.
Addiction stems from activation of the mesolimbic dopamine system causing increases in
dopamine response and pleasurable feelings that are associated with drug reward.
Discontinuation of drug use causes a dopamine-depleted state that has been referred to as the
dopamine depletion hypothesis or also the general anhedonia model. Behavioral studies with
cocaine show that dopamine depleted animals exhibit higher self-administration of cocaine than
subjects with normal levels of dopamine, suggesting involvement of dopaminergic systems in
the Nacc and the reinforcing and motivational effects of addictive drugs (Gerrits & Van Ree,
1996). Additionally, subjects with higher levels of dopamine exhibit lower levels of selfadministration of cocaine. These behaviors are inversely correlated to extracellular levels of
dopamine in the nucleus accumbens. Findings have shown that the use of dopamine agonists to
treat cocaine addiction did not lower self-administration of cocaine, suggesting that the
reinforcing properties of cocaine may not be related to dopamine but instead to the serotonergic
system (Adinoff, 2004).
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Although reward and addiction are mediated by different systems, these systems do
overlap, therefore, creating a connection between the two behaviors (Adinoff, 2004).
The sensitization hypothesis suggests that repeated exposure to a drug causes heightened
sensitivity of the dopamine system because of use of the drug. Behavioral studies have shown
sensitization to cocaine is a causal link to cocaine addiction. The prediction of this hypothesis
says that use of dopamine antagonists would decrease the use and self -administration of cocaine.
However, double-blind placebo testing showed that dopamine antagonists did not decrease the
use and self- administration of cocaine by those who were previously sensitized to the drug. This
finding suggests that addiction may be controlled by more than just an increase or decrease in
absolute levels of dopamine (Badanich & Kirsteina, 2004) and may be because of changes at the
receptor level, as both D1 and D2 antagonists are known to produce a significant increase in
dopamine receptor number (Ahmed & Koob, 2004).
Dopamine, Schizophrenia, and Addiction: A Common Tie?
Interestingly, addiction to certain drugs such as alcohol and amphetamine as well as
prenatal exposure to particular drugs such as cocaine have also been shown to increase
sensitivity of dopamine receptors. The discovery of changes in dopamine receptor function
points to a shared underlying mechanism in both drug addiction and psychoses (Cuffel, 1992). It
is known that the occurrence of cigarette smoking is more than four times as prevalent in the
schizophrenic population than in the general population, which has been suggested to be because
of nicotine’s ability to reduce the negative side effects of neuroleptic medication, likely because
of its effects on the dopaminergic system (Dalack, Healy, & Meador-Woodruff, 1998).
The positive reinforcing effects of nicotine are mediated primarily by the mesolimbic
dopamine system. Research has shown that nicotine increases extracellular dopamine in the
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nucleus accumbens through its action on presynaptically located nicotinic receptors on
dopaminergic neurons (Wilkie, Hutson, Sullivan, & Wonnacott, 1996). Nicotine acts by binding
to ionotropic nicotinic receptors located on the presynaptic side of the neuron, opening these
receptors, and increasing release of dopamine through entry of calcium into the terminal.
Calcium enters through these nicotinic receptors and binds to the protein calmodulin that
subsequently acts to bring synaptic vesicles containing neurotransmitter to the membrane surface
and release neurotransmitter (Julien, 2004).
This increase of dopamine release induced by nicotine has been hypothesized to play an
important role in the reinforcing and locomotor stimulation effects of nicotine. For example,
nicotine has been shown to increase locomotor sensitization when locally injected into the VTA
(Leikola-Pehlo & Jackson, 1992). The ability of nicotine to induce increased locomotion and
also conditioned place preference (Badanich & Kirsteina, 2004) suggests that nicotine has
psychostimulant and addictive properties (Picciotto & Wickman, 1998). The increase in
behavioral responding to nicotine has been shown through a number of behaviors including
increased locomotion and increased vertical rearing behavior, as well as dopaminergic related
behaviors such as paw treading and grooming. It is understood that other neurotransmitter
systems are also involved in this phenomenon, but this may be attributed to modulation of other
systems because of increased release of dopamine in the VTA-nucleus accumbens pathway
(Church, Cotter, Bramon, & Murray, 2002; Crook, Tomaskovic-Crook, Copolov & Dean, 2001;
Leonard & Giordano, 2002).
Psychostimulant Abuse and Schizophrenia
Two hypotheses have been proposed to explain the higher incidence of substance abuse
in schizophrenics. The first hypothesis is that schizophrenics use psychostimulants as a form of
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self-medication because of the processes of the disease. It has been suggested that schizophrenics
use nicotine to alleviate sensory gating abnormalities and attentional deficits caused by the
disorder. (Adler et al., 1998; Adler, Friedman, Ross, Olincy, & Waldo, 1999; Le Duc &
Mittleman, 1995).
The second hypothesis suggests that schizophrenics may be using psychostimulants to
alleviate the negative side effects (depression, anhedonia, apathy, and lethargy) of chronic
neuroleptic treatment. Schizophrenic patients report similar reasons for smoking as do normal
smokers. These include reduction of stress, anxiety, and agitation. They also report similar
withdrawal symptoms as compared to normal smokers, with the addition of some patients
reporting an increase of psychiatric symptoms during withdrawal (Dalack, 1996; Healy &
Meador-Woodruff, 1996). Research has shown that use of certain neuroleptics causes an increase
in cigarette smoking in schizophrenic patients because of dopamine D2 receptor blockade. For
example, Dawe , Gerada, Russell, and Gray (1995) showed that the typical antipsychotic and
potent dopamine D2 receptor antagonist haloperidol administered to normal non-schizophrenic
smokers caused an increase in smoking as compared to baseline. It is believed that this is
because of a decrease in function of dopamine receptor sites, namely the D2 receptor, producing
an increase in nicotine intake to compensate for a lack of dopamine-related reward.
It has also been suggested that schizophrenic smokers extract more nicotine from a
cigarette than do non-schizophrenic smokers, possibly increasing nicotine’s addictive properties.
Research by Olincy, Young, and Friedman (1997) has shown that schizophrenics have an
increased amount of cotinine, a metabolite of nicotine, over non-schizophrenic smokers. It is
believed that schizophrenics have a different pattern of inhalation, allowing increased amounts of
nicotine to be extracted from each cigarette (Olincy et al.). Schizophrenics increase the intensity
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of inhalation, rate of inhalation, and depth of inhalation to hypothetically increase the amount of
nicotine delivered to the system, allowing the user to control the amount of nicotine absorbed
(Hukkanen, Jacob, & Benowitz, 2005). Increased amounts of nicotine may target the low affinity
alpha 7 receptor, which is associated with sensory deficits in schizophrenia, providing an
increased ability for selective attention and possibly alleviating cognitive dysfunction (Leonard
et al., 2001).
Atypical antipsychotic drugs cause schizophrenic patients to experience decreased
feelings of reward (Green, Salomon, Brenner, & Rawlins, 2002; Green, Zimmet, Strous, &
Schildkraut, 1999) as they reduce the amount of dopamine in the brain because of D2 receptor
antagonism. Blockade of the D2 receptor has been shown to produce significantly reduced
motivation, goal-oriented behavior, emotion, and anhedonia. The use of antipsychotic drugs has
also been shown to cause upregulation of the D2 receptors in the brain, possibly explaining
potential abuse of antipsychotics by schizophrenic patients, because the increase in receptors
may lead to increased drug craving or may be synergistic to a patient’s current drug addiction
(Joyce, 2001; McEvoy, Feudenreich, Levin, & Rose, 1995). Reinforcement pathways in the brain
have also been shown to be affected by drugs of abuse and are stimulated by drugs that produce a
sense of euphoria. Stimulation of this system reduces anhedonia, increases goal-oriented
behavior, and alleviates depression like symptoms (Di Chiara et al., 2004). Based on research
that has prevalently shown schizophrenics have increases in sensitivity of the dopaminergic
system, a possible mechanism for increased psychostimulant use in this population is that these
drugs are increasing dopaminergic activity in an already sensitized dopaminergic system, that
results in a significant increased euphoric reaction within the schizophrenic population (Leonard
et al., 2001).
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Nicotine Addiction
Nicotine’s addictive properties are thought to be a result of nicotine’s effects on the
dopamine system. Evidence suggests that nicotine may act directly at presynaptically located
ionotropic nicotinic receptors located on dopaminergic neurons. When these receptors are bound,
they allow for calcium to enter the presynaptic terminal, which acts to increase dopamine release
in the drug reinforcement pathway (Srinivasan & Thara, 2001). By smoking cigarettes, the
schizophrenic patient receives rapid reinforcement of the drug via rapid activation of the
dopamine system. Because of rapid absorption of nicotine and the drug readily entering through
the blood-brain barrier, behavioral reinforcement is strengthened through smoking cigarettes
versus alternative forms of administration of nicotine, which also increases dependence of the
drug (Hukkanen et al., 2005).
Why are Schizophrenics More Likely to Smoke Cigarettes Than the Normal Population?
Several hypotheses have been proposed to explain why schizophrenics are more likely to
smoke cigarettes than the normal population. It has been shown that schizophrenics have an
altered acetylcholinergic system as compared to normal non-schizophrenics, in that
schizophrenics have been shown to have fewer nicotinic receptors, with the largest deficit found
in the hippocampus (Hernandez & Terry, 2005). Deficiency of nicotinic receptors may cause
increased anhedonia and a decrease in the rewarding effects of nicotine. Because of the
deficiency of nicotinic receptors, it has been hypothesized that schizophrenic patients smoke
cigarettes in an effort to self medicate by increasing stimulation to nicotinic receptor sites that
may alleviate side effects caused by neuroleptic use (Leonard et al., 1998). Other hypotheses
have suggested that nicotine may be used by this population to alleviate cognitive impairment
(Elvevag & Goldbeg, 2000) or sensory gating deficits known to exist in schizophrenia (Braff,
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Geyer, & Swerdlow, 2001; Geyer et al., 2001;). However, this research is speculative at this
point, and there is no widely accepted mechanism for the significant increased use of nicotine in
the schizophrenic population.
Modeling Schizophrenia in Rodents: Rodent Models of Neurological Disease
Rodent models of neurological disease are useful for studying components of specific
diseases, but not necessarily for an entire disease itself. Animal models may be used to study the
cause of a disease or to compare treatments for a particular disease but may not be able to predict
the progression of the disease over a lifetime. Animal models may be useful for development
and discovery of new and more effective treatments for neurological disorders (Woodruff &
Baisden, 1994). In most cases, animal models of neurological disease and dysfunction are used
to model one aspect of the disorder: behavioral, neurochemical, or neuropathological. This can
be extremely useful because it can be informative about the contribution of this behavioral or
neurochemical abnormality to the disease or disorder, although the entire disorder is not modeled
in the animal. Additionally, animal models have been used extensively for testing antipsychotic
drugs because of the high genetic homology between rodents and humans, therefore supporting
the use of animals to model neurological disease (Gainetdinov, Mohn, & Caron, 2001).
Past Rodent Models of Schizophrenia
Schizophrenia is a difficult disorder to model because of its complexity and because it
affects several neurotransmitter systems and brain areas. Therefore, most rodent models of
schizophrenia have focused on one particular neurochemical or neuropathological abnormality
produced by the disease. Several rodent models of schizophrenia have been used to test different
behavioral deficits and the effects of drugs on these behavioral deficits as well as on
neurochemical changes produced by the pathology of the disorder.
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Latent Inhibition Model
The amphetamine-haloperidol latent inhibition model of schizophrenia was proposed by
Solomon et al. (1981) and Weiner et al. (1981) and has since been replicated by many other
researchers. Latent inhibition (LI) is a learning phenomenon first described by Kamin (1968) that
demonstrated pre-exposure to a conditioned stimulus (CS) produces a deficit in acquisition of a
CR when the same CS is temporally paired with an unconditioned stimulus (US). Results have
shown that amphetamine also disrupts conditioning of the CS thus producing a similar
phenomenon as LI. The LI deficit is then reversed through use of atypical and typical
antipsychotic drug pretreatment (Weiner, Schiller, & Gaisler-Salomon, 2002) given before
amphetamine administration. This model is said to mimic the positive symptoms of the disease
with face, construct, and predictive validity because these symptoms are also seen in humans
with schizophrenia and schizotypal disorder and in normal subjects being exposed to
antipsychotic drugs. This model focuses on the nucleus accumbens and dopamine innervation
from circuitry involved in LI, which are involved in the conditioning phase of the model.
Phencyclidine (PCP) Model
Heresco-Levy, Silipo, and Gavit (1996) have used a rodent model of schizophrenia
through acute administration of phencyclidine (PCP). This model suggests that use of the drug
PCP induces schizophrenia-like symptoms in normal subjects. This drug acts by blocking the
PCP binding site located on the glutamatergic N-methyl-D-asparate (NMDA) receptor, acting as
an inverse agonist. This model focuses on blockade of NMDA receptors as a way of inducing
schizophrenia-like symptoms because schizophrenics have also been shown to demonstrate
hypoactivity of the NMDA receptor (Hersco-Levy et al.; Millan, 2002, 2005). By binding to
noncomptetitive NMDA sites, this model is able to produce both positive and negative
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symptomology, whereas the amphetamine-LI model induces primarily positive symptoms of the
disease. Findings with this model suggest that targeting the NMDA receptor site may lead to
alleviation of both positive and negative symptoms of schizophrenia. Behavioral studies have
shown that use of agonists at the NMDA receptor, such as a glycine agonist or D-serine, resulted
in alleviation of positive and negative cognitive symptoms (Heresco-Levy et al.).
Neonatal Hippocampal Lesion Model
One of the more often used and well-validated rodent models of schizophrenia is the
neonatal ventral hippocampal lesion model developed by Lipska and Weinberger (Lipska,
Jaskiw, & Weinberger, 1993; for review see Lipska, 2004). This model is based on hippocampal
dysfunction because schizophrenics show a significant increase in size of the lateral ventricles
and significantly smaller hippocampi than normal subjects (Eastwood & Harrison, 1999). In this
model, animals are given neonatal ventral hippocampal lesions at postnatal day 7 (P7). Several
studies have shown that ablation of the ventral hippocampus during development leads to
abnormalities in adulthood of numerous dopamine-related behaviors specific to schizophrenia.
For example, rats with neonatal lesions exhibit faster cocaine self-administration and have a
greater incidence of binge-like cocaine intake than control subjects, suggesting a higher
susceptibility to psychostimulant abuse (Lipska et al.). Additionally, this model mimics the
effects of changes in DA and GABA markers of mRNA in various regions of the brain that are
also seen in human schizophrenics. The neonatal lesion has shown a significant reduction in
expression of dopamine transporter (DAT) mRNA in the substantia nigra and VTA as adults.
However, adult lesions do not show changes in expression (Lipska, 2003). Behaviorally,
neonatal hippocampal lesions produce several behavioral deficits consistent with schizophrenia
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including hyperlocomotion, pre-pulse inhibition deficits, social withdrawal, and isolation (SamsDodd, 1997) as well as cognitive impairment (Chambers, Moore, McEvoy, & Levin, 1996).
Weaknesses of Past Rodent Models of Schizophrenia
There are two primary weaknesses of past rodent models of schizophrenia. First, several
models have used high doses of drugs that produce neurochemical abnormalities that are similar
to schizophrenia. These animal models of dopaminergic hyperactivity do not effectively
reproduce the effects of long-term increases in dopaminergic activity as is observed in
schizophrenia. In the neonatal hippocampal lesion model, the primary weakness is that there has
not been definitive evidence of cell death in the hippocampus in human schizophrenics
(Harrison, 1999; Harrison & Eastwood, 2001, 2004). Therefore, there are some weaknesses in
this model that may not be accurate relative to the neuropathology in schizophrenia.
A New Rodent Model of Schizophrenia
Studies from this laboratory have shown that neonatal quinpirole treatment in rats
produces a marked D2 supersensitization that lasts throughout the animal’s lifetime. Dopamine
D2 supersensitization, a phenomenon also known as ‘priming,’ is manifested behaviorally
through hyperlocomotion, increased vertical rearing, increased horizontal activity, and increased
yawning. Past research has shown that acute nicotine treatment produces a partial or total block
of the effects of the ontogenetic quinpirole treatment on spatial memory tasks (Brown et al.,
2002; 2004a; 2004b; 2005) and dopamine-related behaviors (Tizabi, Copeland, Brus, &
Kostrzewa, 1999).
Why This is a Valid Rodent Model of Schizophrenia
The D2 priming model as induced by neonatal quinpirole treatment is an accurate model
of schizophrenia for several reasons. Certain physical aspects of schizophrenia suggest that the
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disease is not because of neuropathology, or cell death in the brain, but because of a
neurodevelopmental abnormality (Domino, Mirzoyan, & Tsukada, 2004). This model
exemplifies the developmental change because neonatal quinpirole treatment takes place during
the developmental stages of dopaminergic pathways. This model exhibits several key behaviors
that are also seen in human patients including prepulse inhibition (PPI) deficits (Maple et al.,
2007, manuscript in preparation), increased dopamine response to amphetamine (Nowak, Brus,
& Kostrzewa, 2001; Nowak, Brus, Oswiecinska, Sokola, & Kostrzewa, 2002), cognitive deficits
(Brown et al., 2004a, 2004b, Green et al., 2002), and significant decreases of neurotrophic
factors such as NGF and BDNF in the hippocampus (Brown, Perna, Schaefer, & Williams, 2006;
Durany et al., 2001; Toyo’oka, 2002). Pretreatment with the atypical antipsychotic olanzapine
(trade name: Zyprexa) has been shown to alleviate deficits in cognitive performance in this
model (Thacker et al., 2006).
Gender Differences
Schizophrenia affects both men and women equally, with a later onset of symptoms in
women than in men. Women experience less hospitalization because of schizophrenia and
function better socially than men. Reasons for later onset of the illness for women are
hypothesized to be because women have higher social functioning before the onset of the illness
than men, and that estrogen can reduce the sensitivity of the D2 receptors in the central nervous
system (McGurk & Mueser, 2004).
Gender Differences in Schizophrenia and Nicotine Abuse.
Past research has shown gender differences in the course and manifestation of
schizophrenia. Schizophrenic women demonstrate a later age onset and higher premorbid and
overall functioning (Bardenstein & McGlashan, 1990; Goldstein & Kreisman, 1988; Symanski et
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al., 1995). Women more often express affective symptomology and are differentially vulnerable
to paranoia and hallucinations (Andia et al., 1995). Men more frequently exhibit flat affect and
suffer from other negative or deficit symptoms (Symanski & Hertz-Picciotto, 1995). Although
there is ample research that demonstrates gender differences in schizophrenia, there is very little
information concerning whether there are gender differences in the impact of nicotine abuse in
the schizophrenic population. Results suggest higher overall functioning observed in women, and
that women schizophrenics smoke less often and are less likely to be substance abusers, fitting
with the lower probability of anhedonia present in women schizophrenics (Gearon & Bellack,
2000; Leung & Chue, 2000). Little research that has been done on gender differences in
schizophrenia and how gender differences and schizophrenia may interact with the use of
nicotine.
The Estrus Cycle in Female Rats and the Effects of Psychostimulants.
The estrus cycle of the female rat has three stages, recurs every 4 days (Finch, Felicio,
Mobbs, & Nelson, 1984), and is functionally equivalent to the menstrual cycle in humans. The
stage of the estrus cycle can be determined by swabbing cells from the vaginal lumen after sterile
wash (lavage) and then examining these cells microscopically. Vaginal estrus lasts 36 hours, and
cornified epithelial cells are present. Vaginal estrus is followed by a period during which
cornified cells become reduced in number, and this stage is called vaginal diestrus with a
duration of 48 hours. The first day of diestrus is referred to as diestrus I, and the second day is
referred to as diestrus II. The next phase is characterized by the presence of many nucleated
epithelial cells and this stage is vaginal proestrus, which lasts for approximately 12 hours. It is
important to understand that behavioral estrus coincides with vaginal proestrus, and there is
elevated estrogen secretion during this period as well as estrous behavior.
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Past studies have shown that psychostimulants given during certain stages of the estrous
cycle enhance dopamine release in the striatum and produce an exaggerated locomotor response.
Becker and colleagues have shown that during behavioral estrus in female rats, amphetamineinduced striatal dopamine release and amphetamine-induced behaviors are greater than on other
days of the estrous cycle (Becker, 1999; Becker & Cha, 1989; Becker, Robinson, & Lorenz,
1982). Additionally, female rats show a greater behavioral response when the striatal dopamine
system is stimulated during behavioral estrus, which is 6-12 h after the surges of estrogen and
progesterone, than they do 24 h later on diestrus and show enhanced sensorimotor function on
behavioral estrus compared to diestrus (Becker et al., 1982; Becker & Cha, 1989; Robinson,
Camp, Jacknow, & Becker, 1982). During proestrus, striatal dopamine uptake sites are the
highest, suggesting a presynaptic effect of gonadal hormones during this phase. Therefore,
coincident with the endogenous surges of estrogen and progesterone during behavioral estrus,
there is enhanced dopaminergic activity, as indicated by enhanced dopamine release,
metabolism, and reuptake (Becker, 1999). Although it appears that there is an increase in
dopamine release in females in response to nicotine and some behavioral and metabolic gender
differences that exist, there is little evidence that the stage of the estrous cycle is critical to this
gender difference. Stage of the estrous cycle was not found to affect nicotine self-administration
as compared to males nor affect the rate of acquisition of nicotine self-administration (Donny et
al., 2000).
Gender Differences and Nicotine Sensitization
There have been complex and sometimes contradictory findings relative to gender
differences in the response to nicotine. Nicotine has been found to produce more robust
locomotor sensitization in female rats than male rats (Booze et al., 1999; Harrod et al., 2004), but
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this does not appear to be related to stage of the estrous cycle (Kuo et al., 1999). Additionally,
recent findings have shown that nicotine administered iv (50 ug/kg) does not affect normal
cycling in females (Harrod et al.) although there is contradictory evidence indicating that a
higher dose of chronic nicotine administered via an osmotic minipump (5mg/kg/day) extends the
proestrus stage of the cycle (Miyata, Meguid, Varma, Fetissov, & Kim, 2001).
Several studies have shown that females are more sensitive to the effects of nicotine.
Rosecrans (1971 1972) reported that female rats are more chemically and behaviorally sensitive
to nicotine than males, and female rats have demonstrated significantly higher endogenous levels
of nicotine in the brain as compared to males, suggesting gender differences in response to
nicotine (Rosecrans, 1972). More recent work has shown that the increase in NAcc dopamine
release is higher in female rats than in males following systemic nicotine treatment (Faraday,
O’Donoghue, & Grunberg, 2003). This result may be related to findings that have shown
estrogen enhances nicotine-induced dopamine release in striatal slices prepared from
ovariectomized rats (Dluzen & Anderson, 1999). However, other findings have shown that this
increase in dopamine release related to the estrogen surge does not correlate with nicotineinduced increases of activity in females (Harrod et al., 2004; Kuo et al., 1999).
Gender Differences in Dopamine Receptor Sensitivity
Several studies have shown gender differences in dopamine receptor sensitivity, as
manifested in changes in locomotor behavior. For example, Schindler and Carmona (2002) have
reported that although females demonstrate a higher sensitivity to the locomotor activating
effects of the dopamine D1 receptor, males demonstrate a higher sensitivity to the locomotor
depressing effects of dopamine D2 receptor activation. In a different study, male and female rats
administered a dopamine D1 agonist were shown to exhibit an initial inhibitory effect followed
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by an increase in activity, and results showed that males were more sensitive to the locomotor
inhibitory effect of the D1 agonist than females, whereas the later hyperactive response was
greater in females (Hejitz et al., 2002). Regarding the D2 receptor, the locomotor stimulatory
effects of quinpirole have been shown to be greater in females than males (Frantz and Van
Hartesveldt, 1999; Szumlinski, Goodwill, & Szechtman, 2000). These results appear to show
gender differences in dopamine receptor sensitivity in that females demonstrate increases of
sensitivity to locomotor stimulatory effects to dopamine agonists and males demonstrate
increases of sensitivity to the locomotor inhibitory effects of dopamine agonists. However, it is
not known how gender differences in the response to nicotine may interact with long-term
increases in sensitivity of dopamine receptors, specifically increases in D2 receptor sensitivity.
Gender Differences in Yawning Behavior, a Dopamine D2 Receptor Mediated Event
Although locomotor activity data may suggest an increased sensitivity of dopamine receptors in
females, we have demonstrated a reverse pattern in yawning behavior in adult rats. Recent data
from this laboratory have shown that males and females neonatally treated with quinpirole both
demonstrate a significant increase in yawning as compared to saline controls when tested for 1
hour after an acute quinpirole injection as adults, but males show approximately a three-fold
increase in yawning compared to females (Brown et al., 2006a). Additionally, early postnatal
male rats demonstrate a more severe deficit in cognitive performance as compared to females
when administered a dopamine D2 antagonist immediately before training (Brown et al., 2005).
These observations suggest that the sensitivity of the D2 receptor in males is increased in its
relationship to cognitive function as compared to females. Regardless, it is very important to
realize that locomotor sensitization, yawning, and cognitive function are three different
behaviors that involve distinctly different brain areas and pathways, and clearly it appears that
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the relationship of gender differences in dopamine D2 receptor sensitivity may affect these
behaviors in very different ways.
Age differences: Adolescent vs. Adult Drug Addiction
Adolescent exposure to drugs of abuse has been shown to have a different outcome from
exposure in adulthood. Special consideration has recently been given to nicotine addiction in
adolescents. This research has shown that adolescent drug exposure leads to greater addiction,
higher consumption, and a decreased rate of quitting as compared to adults (Chen et al., 1998).
Age-related changes have also been found in gene expression and in cell number, along with a
long term change in the reward pathway of adolescents (Kelley & Middlaugh, 1999). Trauth,
McCook, Siedler, and Slotkin (2000) have shown that adolescent nicotine exposure produces
significantly decreased cholinergic activity in the hippocampus during drug treatment but not in
other regions of the brain, and these changes persist for up to 1 month posttreatment. This
supports the hypothesis that this is a critical time period for change in certain brain areas of the
adolescent rat.
Dopamine System Differences in the Adult vs. the Adolescent Brain
Research by Haycock et al. (2003) suggests that the difference between the dopamine
system between adolescents and adults can be explained by neural organization and
development. In humans, during the first 2 years of life, the dopamine system is undergoing
significant growth, which continues until about the age of 30, where growth tends to taper off
and eventually, in later adulthood, dopaminergic growth declines and cells begin to die in
advanced age. However, during adolescence, the growth of the dopamine system is more rapid
and elaborate because of reorganization and remodeling of the innervation of the dopamine
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system. During this time, growth is especially observed in the prefrontal cortex and in the
mesolimbic pathways, including the growth of dopaminergic pathways in all areas (Spear, 2000).
Badanich and Kirsteina (2004) have reported behavioral and neurochemical differences
because of nicotine exposure in adult versus adolescent rats. Animals were treated with acute or
chronic nicotine exposure during early adolescence, late adolescence, or early adulthood. Acute
nicotine exposure in adult animals showed an increase in the dopamine release in the nucleus
accumbens in response to a nicotine challenge, while adolescents did not demonstrate a
significant increase in dopamine release. Interestingly, chronic exposure did not increase the
dopamine response in adolescents or adults. These results suggest that acute exposure to nicotine
in adults may cause a significant increase in dopamine response that is not apparent after
repeated exposures because of tolerance to the drug. Additionally, other behavioral studies have
shown that adolescent animals exposed to nicotine in a conditioned place preference paradigm
prefer the drug paired chamber to the non-drug paired chamber, whereas adults do not show this
preference for the drug paired chamber (Torella et al., 2004). All of these results suggest
different organization of the dopamine system in the adolescent versus the adult.
Nicotine’s Effects on Adolescent Behavior and Importance
Because adolescence is a critical time for the reorganization of neuronal pathways, these
individuals are more susceptible to the addictive effects of drugs of abuse (Adriani et al., 2004).
During adolescence, individuals are more likely to seek out new situations, sensations, and risks
making them more likely to try new things, including drugs. Research has shown that drug
exposure and drug use in adolescence may contribute to drug use and addiction later in life. Two
explanations for this early exposure effect are that early exposure may alter the development of
critical brain areas at that time, and that novelty seeking behavior in adolescence may predict
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later abuse. Barron et al. (2005) has shown that pre-teen exposure to nicotine is predictive of
alcohol abuse.
Research by Trauth, Siedler, Ali, and Slotkin (2001) and Slotkin et al. (1999) has shown
that adolescent exposure to nicotine produces an overall change in the structure and upregulation
of nicotinic receptors that differs from what is obsesrved during adult exposure to nicotine.
Robust receptor upregulation has been shown in both adolescents and adults, but there were
major differences in the regional specificity and persistence of effect. In adolescents,
upregulation was uniform across all regions during the infusion period, whereas in adults, there
was a distinct regional hierarchy: midbrain < cerebral cortex < hippocampus. Accordingly,
receptors in the adolescent midbrain were upregulated far more than with adult exposure. In
addition, adolescent nicotine treatment produced long-lasting effects on the receptors, with
significant increases still apparent in male rats 1 month after the termination of drug exposure,
whereas this was not the case in adults. Additionally, evidence for hippocampal cell damage has
been shown in adolescent female rats exposed to nicotine, characterized by increases in total
membrane protein concentration indicative of a decrease in overall cell size. Adolescent nicotine
exposure thus elicits region- and gender-selective effects that differ substantially from those in
adults, effects that may contribute to increased addictive properties and lasting deficits in
behavioral performance. Other research has shown that brain areas rich in dopamine, mainly the
prefrontal cortex and the mesolimbic regions of the brain, show marked changes and
development during adolescence (Spear, 2000).
Competing Theories of Differences in Adolescent and Adult Responses to Drugs of Abuse
There are two competing theories for the underlying mechanisms of adolescent addiction
to drugs of abuse. The first theory states that adolescents have underdeveloped neural circuitry
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that may underlie impulsivity and addiction vulnerability. According to this theory, adolescents
are less likely to consider the negative repercussions of behavior, more likely to base decisions
on proximal outcomes rather than distal outcomes, and may be better motivated by reward than
by punishment. During this time, the activation of the ventral striatum is disproportionately
higher than the influence of the inhibitory circuits (Kelley, Schochet, & Landry, 2004).
The second theory states that risky behavior in adolescence results from a relatively
overactive ventral striatal motivational circuit that readily approaches salient appetitive cues
(Cardinal, Winstanley, Robbins, & Everitt, 2004) Behavioral studies have shown that
adolescents are more motivated by immediate rather than delayed reinforcement. Because of
underdeveloped circuits, adolescents do not maintain motivation for gain between performing a
behavior and waiting for the reward, making them more motivated by immediate reinforcement
(Badanich & Kirsteina, 2004).
Neurotrophic Factors
Neurotrophic factors in the brain were originally thought only to control the growth and
differentiation of cells in the brain during development but are now known to play a major role
in regulating plasticity and survival of adult glia and neurons (Shoval & Weizman, 2005).
Recently, Hashimoto, Shintani, and Baba (2006) showed that alteration of neurotrophic factors
during different stages in development may lead to pathological disorder. In schizophrenia, it has
been shown that size abnormalities in the entorhinal, cingulate, and prefrontal cortex stem from
disruptions in proliferation in early corticogenesis causing marked damage to these areas. In
development, there are increased levels of neurotrophic factors in the hippocampus as compared
to other brain areas. Also, findings show that schizophrenics have a reduced amount of
neurotrophins in brain tissue supporting the hypothesis of their involvement in the
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neuropathology of the disease (Durany et al., 2001, 2004; Shoval & Weizman, 2005). Reductions
in the prefrontal cortex and entorhinal and cingulate cortex areas of the brain lead to alterations
in the synthesis and release of certain neurotrophic factors, namely nerve growth factor (NGF)
and brain-derived neurotrophic factor (BDNF) (McGurk & Meuser, 2004). Reductions in these
areas are also found in the brains of schizophrenic patients.
Research has shown that chronic drug exposure causes changes in neurotrophic factors,
typically NGF and BDNF, which may lead to psychostimulant addiction. Nicotine has been
shown to produce a significant increase of both NGF and BDNF in the hippocampus and in
frontal cortex (Brown et al., 2006b; French et al., 1999). Although other psychotimulants, such
as cocaine and amphetamine have been shown to produce a significant increase in BDNF in the
nucleus accumbens, there is no information relative to the effects of nicotine on this important
brain area in drug reward. However, Brown and Kolb (2001) have shown that exposure to
nicotine produes a 35% increase in spine length and density of dendrites in the nucleus
accumbens, suggesting the possibility of changes in neurotropphic factors in the nucleus
accubmens.
Research Problem
Research has shown that there is a significant increase in dopamine (DA) function in
schizophrenia, especially at the dopamine D2 receptor (Nissel, Marcus, Nomikos, & Svensson,
1997). Kostrzewa et al. (1995) have shown that neonatal quinpirole (a dopamine D2/D3 agonist)
treatments produce long-term increases in D2 receptor sensitivity that persists throughout the
animal’s lifetime. Koeltzow, Austin, and Vezina (2003) have shown that blockade of DA
receptors block increases of locomotor activity and that chronic treatment of quinpirole produces
locomotor sensitization. In addition, nicotine produces increases in locomotion, which can also

28

be blocked by blocking the D2 receptor (Clarke, Fu, Jakubovic, & Fibiger, 1988). Brown et al.
(2006) have shown that neonatal quinpirole treatment produces decreased levels of nerve growth
factor (NGF) and brain derived neurotrophic factor (BDNF) in the hippocampus, and that this
deficit is alleviated by nicotine treatment in adulthood.
There is little information on the difference between adolescent and adult rats on
sensitization to nicotine, and there is no information as to how this variable may interact with
priming of the D2 receptor, gender differences in behavior, nor how this may be manifested in
differences in BDNF in brain areas known to mediate drug reward in D2-primed and non D2primed rats. In Experiment 1, both male and female rats will be neonatally treated with
quinpirole, a dopamine D2/D3 agonist, which has been shown to prime the dopamine D2
receptor. We will sensitize both D2-primed and non D2-primed male and female adolescent and
adult rats to nicotine. Postmortem, the NAcc will be assayed for BDNF.
The aim of this thesis is two -fold: 1) To measure behavioral differences, namely
increases or decreases in locomotor activity, in D2-primed and non-primed male and female
adolescent and adult Sprague-dawley rats; 2) Analyze differences in brain derived neurotrophic
factor (BDNF) in the nucleus accumbens, a brain area important in the rewarding effects of
nicotine. We hypothesize that: Animals neonatally treated quinpirole (D2-primed) will show
increased activity as compared to animals neonatally treated with saline and D2-primed animals
administered nicotine will show more robust sensitization as compared to all other groups.
Female animals will show more increased sensitization than males, with D2-primed females
administered nicotine demonstrating the most robust sensitization over all groups. As for BDNF,
we hypothesize that neonatal quinpirole treatment will cause a decrease in BDNF in the nucleus
accumbens and that adolescent or adulthood nicotine treatment will alleviate the deficit.
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CHAPTER 2
METHODS
Subjects
Adolescent animals were 35 days old and were randomly assigned to drug groups by
gender and neonatal treatment. Animals were derived from eight litters and were assigned as
follows (the first drug represents neonatal treatment and the second drug represents adolescent
drug treatment): Quinpirole-Nicotine, four females and seven males; Quinpirole-Saline, five
females and eight males; Saline-Nicotine, four females and seven males; Saline-Saline, four
females and seven males.
Adult animals were 60 days old and were randomly assigned to drug groups by gender
and neonatal treatment. Animals were derived from seven total litters and were assigned as
follows (the first drug represents neonatal treatment and the second drug represents adult drug
treatment): Quinpirole-Nicotine, six females and seven males; Quinpirole-Saline, five females
and five males; Saline-Nicotine, five females and seven males; Saline-Saline, six females and
five males.
Neonatal Drug Treatment
Animals were given a single daily intraperitoneal (i.p.) injection of either quinpirole
(1mg/kg) or saline from postnatal day 1-21 (P1-21). All animals were administered 1mg/kg
quinpirole based on body weight. Different groups of male and female rats were raised to
adolescence (P30) or adulthood (P60).
Habituation to the Locomotor Arena
The day following the yawning test (which is used to verify D2 supersensitivity), all
animals were given i.p. injections of saline for the next 3 testing days and all animals were
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placed in the locomotor arena (30 cm on a side) covered by a grid of white lines. This task
provided a baseline activity measure and habituated the animal to the locomotor apparatus. There
were four groups, with the first treatment administered neonatally and the second treatement
administered in adolescence or adulthood: Saline-Saline, Saline-Nicotine, Quinpirole-Saline,
Quinpirole-Nicotine.
Locomotor Sensitization
Following habituation, half of the animals were given i.p. injections of nicotine tartarate
(0.5 mg/kg free base) and the other half were given saline every second day. Fifteen minutes
after each injection the animals were placed in the locomotor arena for 10 minutes and the
number of grid line crossings were recorded by an experimenter, which served as a measure of
horizontal activity. Testing was performed for 9 days in all groups.
Procedure, Research Design, and Analysis
Animals were randomly assigned to each drug condition, with one animal per drug
condition from each litter to control for across litter variability. For initial analyses of locomotor
activity, a four -way ANOVA was used. The independent variables were two between groups of
neonatal drug treatment (Quinpirole or Saline), adolescent or adulthood drug treatment
(Between: Nicotine, Saline), sex (Between: Male, Female), and trial block (Three within levels:
Trial block 1, 2, and 3). The dependent variable was the number of horizontal line crossings. The
trial block measure was the average of three daily training sessions. Fisher’s LSD tests were used
for the post hoc test (alpha level = .05).
BDNF Procedure
Twenty-four hours after testing, the brains were harvested and flash frozen in cold
isopentane (-20oC) and stored at -80C. Nucleus accumbens (Nacc) was dissected from the
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tissue samples and homogenized in a RIPA cell lysis buffer. After homogenization, tissue
samples were analyzed using a BDNF sandwich ELISA kit purchased from Promega (Madison,
WI). For the BDNF assay, 10 l of the anti-BDNF monoclonal antibody (mAb) was added to
9.99 ml of carbonate coating buffer (pH 9.7). To each well of the ELISA plate, (Nunc,
MaxiSorp, 96 well polysterene plate) 100μl of the carbonate coating buffer was added and
incubated overnight at 4˚ C to coat the plate. All wells were washed with PBS-T and incubated at
room temperature for 1 hour. Nonspecific binding was blocked with 1x block and sample buffer
and incubated at room temperature for 1 hour. The BDNF standard curve was prepared using
serial dilutions of the BDNF standard supplied by the manufacturer (1g/ml). The standard was
diluted 1:2,000 to achieve a concentration of 500 pg/ml. The Nacc was further diluted 1:2 prior
to being assayed. The standards and samples were incubated with shaking at room temperature
for 2 hours. Anti-Human BDNF pAB was then added to each well plate, incubated at room
temperature for 2 hours, which was followed by incubation (1hour) with Anti-IgY horseradish
peroxidase (HRP) conjugate. Finally, 100 l of TMB one solution was added to each well and
incubated at room temperature to achieve color transformation. The reaction was stopped by
adding 1N hydrochloric acid and read within 30 minutes using a Biorad plate reader. Optical
density was measured using a Biorad 96-well plate reader.
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CHAPTER 3
RESULTS
Gender Differences in Adolescents
Horizontal Activity for Adolescent Females
Horizontal activity is presented as a function of week of testing in Figure 1. A 2 x 2 x 3
repeated measures ANOVA revealed a significant two-way interaction of Neonatal Drug
Treatment x Adolescent Drug Treatment F(1,22) = 9.95, p<.009 and Adolescent Drug Treatment
x Week of Testing F(2,22) = 5.42, p<.01. The Fisher's LSD post hoc test revealed a significant
decrease in activity in D2-primed and non D2-primed animals receiving nicotine in week 1. D2primed animals demonstrated a significant increase in locomotion as compared to saline animals
in week 2, but not in weeks 1 or 3; however, the decrease in activity in the Q-N group in week 3
was because of increases in stereotypic behavior (notated by #). Nicotine induced a decrease in
activity in both D2-primed and non D2-primed animals as compared to saline controls in the first
week of testing.

Figure 1. Horizontal Activity for Adolescent Females
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Horizontal Activity for Adolescent Males
Horizontal activity is presented as a function of week of testing in Figure 2. A 2 x 2 x 3
repeated measures ANOVA revealed a significant main effect of adolescent drug treatment
F(1,25) = 10.34, week of testing F(2,25) = 46.88, p<.001, a significant two-way interactions of
Neonatal Drug Treatment x Adolescent Drug Treatment F(1,25) = 8.14, p<.009 and Adolescent
Drug Treatment x Week of Testing F(2,25) = 13.47, p<.001. The Fisher's LSD post hoc test
revealed that D2-primed males receiving nicotine did not show a decrease in week 1 as
compared to non D2-primed males receiving saline. However, non D2-primed males receiving
nicotine did show a decrease in activity in week 1. In week 2, D2-primed males receiving
nicotine showed a significant increase in activity as compared to all other groups. In week 3,
D2-primed and non D2-primed animals receiving nicotine showed increased activity as
compared to animals receiving saline, but these two groups were equivalent. Interestingly, D2primed males receiving saline did not show increased activity over non D2-primed animals
receiving saline.

Figure 2. Horizontal Activity for Adolescent Males
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Gender Differences in Adults
Horizontal Activity for Adult Females
Horizontal activity is presented as a function of week of testing in Figure 3 for adult females.
A 2 x 2 x 3 repeated measures ANOVA revealed a significant main effect of neonatal drug
treatment F(1,18) = 4.74, p<.04, a significant main effect of week of testing F(2,18) = 67.15,
p<.001, a significant interaction of Neonatal Drug Treatment x Week of Testing F(2,18) = 5.71,
p<.007 and a significant interaction of Adulthood Drug Treatment x Week of Testing F(2,18) =
21.88, p<.001. The separate analysis of estrous cycle revealed no significant main effects or
interactions involving the stage of the estrous cycle (all effects p>.01). This is consistent with
past data that have shown stage of the estrous cycle in female rats does not interact with nicotine
behavioral sensitization (Booze et al., 1999). Fisher LSD post hoc tests revealed D2-primed
females administered nicotine demonstrated a significant increase in activity relative to all other
groups in week 3. Nicotine induced a significant decrease in initial activity in both and D2primed and non D2-primed rats compared to controls administered saline. D2-primed females
demonstrated a significant increase in activity relative to controls and statistically equivalent
levels of activity compared to controls administered nicotine in week 3 (notated by #). D2primed females administered saline showed a significant increase in locomotor activity as
compared to non D2-primed animals administered saline. This significant increase in locomotion
persisted throughout the 3 weeks of training.
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Figure 3. Horizontal Activity for Adult Females
Horizontal Activity for Adult Males
Horizontal activity is presented as function of week of testing in Figure 4 for adult males.
A 2 x 2 x 3 repeated measures ANOVA in males revealed a significant main effect of adulthood
drug treatment F(1,20)=13.47, week of testing F(2,20)=32.48, and a significant interaction of
adulthood drug treatment x week of testing F(2,20)=19.06, p<.001. Fisher LSD Post hoc tests
revealed: D2-primed males administered nicotine demonstrated a significant increase in activity
relative to all other groups in week 3 of testing. Male rats administered nicotine did not
demonstrate the typical initial nicotine-induced hypoactivity in week 1 of testing, but nicotine
produced a significant increase of activity in males at weeks 2 and 3. Control animals
administered nicotine demonstrated a significant increase in activity relative to D2-primed and
non D2-primed animals given saline at weeks 2 and 3. Unlike females, D2-primed males treated
with saline did not demonstrate a significant increase in horizontal activity over the 3 weeks of
testing.
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Figure 4. Horizontal Activity for Adult Males
BDNF Results
Adolescent BDNF Results
A two-way ANOVA revealed a significant main effect of sex F(1,21) = 8.32, p<.009,
drug F(1,21) = 5.67, p<.027, and an age main effect F(1,21) = 4.77, p<.027. For adolescents,
there was no significant main effect of neonatal drug treatment on BDNF levels (Figure 5), as
was seen in adults (see Figure 6). However, there was a significant main effect of gender that
was not seen in adults. Females administered nicotine during adolescence showed increased
BDNF levels over all groups, while male animals administered nicotine during adolescence did
not show an increase over male animals administered saline during adolescence.
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Figure 5. Adolescent BDNF Results
Adult BDNF Results
A two-way ANOVA revealed no significant main effects of neonatal drug treatment nor
adulthood drug treatment, but the interaction of Neonatal Drug Treatment x Adulthood Drug
Treatment was significant F(1,28) = 6.35, p<.017. Fisher’s LSD tests revealed that D2-primed
animals administered saline demonstrated a significantly lower level of BDNF relative to all
other groups, demonstrating that nicotine treatment reversed the decrease in BDNF produced by
neonatal qunpirole treatment.
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Figure 6. Adult BDNF Results
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CHAPTER 4
DISCUSSION
These results suggested that neonatal treatment with the dopamine D2/D3 agonist
quinpirole resulted in dopamine D2-receptor priming that resulted in more robust behavioral
sensitization to nicotine in both adolescent and adult rats. Previous studies have shown that
nicotine increases dopaminergic neurotransmission through its agonist action at nicotinic
receptors located presynaptically on dopamine terminals (Marshall, Redfem, & Wonnacott,
1997). Because nicotine acts to increase dopamine release on primed postsynaptically-located D2
receptors, a significantly increased dopaminergic response to nicotine explains the more robust
sensitization to nicotine observed in the present study. However, there were significant age and
gender differences in response to neonatal, adolescent, and adulthood drug treatment, and these
will be discussed below.
Adolescent Results
Overall, D2-primed male and female adolescent rats administered saline showed a
significant increase in activity as compared to non D2-primed animals, consistent with previous
reports from Frantz and Van Hartesveldt (1999), which showed increased locomotor activity
because of repeated exposures to quinpirole. However, D2-primed females administered saline
showed a significant increase over all groups in the first week of testing but did not show a
significant increase in locomotion over the 3 weeks of testing. Interestingly, D2-primed
adolescent male rats administered saline demonstrated a slight but significant increase over the 3
weeks of testing, although not equal to the magnitude of the females. This finding appears to be
consistent with past findings showing that there are sex differences in the D2 receptor that are
manifested in changes in activity, and adolescent females demonstrated both increased D2
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sensitivity and significant increases in activity (Frantz & van Harestveldt, 1999; Schindler &
Carmona, 2002).
Both D2-primed and non D2-primed adolescent males and females treated with nicotine
showed a significant increase in locomotor activity over the 3 weeks of testing as compared to
saline treated control animals, with the most robust increase in locomotor activity observed
during the third week of testing. This is consistent with past data by Adriani et al. (2006) that
showed increased behavioral effects of nicotine in adolescent animals, with increased locomotor
activating effects occurring because of repeated nicotine administration.
During the first week of testing, D2-primed males did not demonstrate a hypoactive
response to nicotine, whereas D2-primed and non D2-primed females as well as non D2-primed
males all demonstrated a hypoactive response to the drug. This result appears to show that
neonatal quinpirole blocks the hypoactive response to nicotine in adolescent males but not in
female adolescents. Faraday, O’Donoghue, and Grunberg (2003) have shown that the hypoactive
response to nicotine is dose-dependent in adolescent males, and a 0.5 mg/kg free base dose
produces a hypoactive response in male adolescents, but neither a lower dose, 0.1 mg/kg, nor a
higher dose, 1.0 mg/kg, produced the same effect. This suggests that adolescent males may be
more sensitive to the locomotor activating effects of the dopamine system because neonatal
quinpirole treatment blocks the hypoactive response to nicotine in this group. This effect may be
because of the receptor sensitivity differences in males as compared to females but also may
suggest that nicotine does not attenuate the hyperlocomotion effects in adolescent males as has
been shown in adult animals (Schindler & Carmona, 2002). Although a past study by Tizabi et
al (1999) using ontogenetic quinpirole treatment has shown that nicotine blocks the locomotor
activating effect of quinpirole in young adolescent rats, Tizabi, et al (1999) used only acute
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nicotine treatment and did not analyze subchronic nicotine treatment across adolescence as in the
present study.
Dopamine D2-primed adolescent females appear to demonstrate a significant decrease in
locomotor activity after subsequent nicotine administrations in weeks 2 and 3. This decrease in
locomotor activity appears on the surface to be paradoxical, as presumably dopamine activity is
increasing with subsequent nicotine administrations, and locomotor activity should positive
correlate with this action. However, upon further observation, we have found that these D2primed female adolescent rats administered nicotine appear to increase stereotypic behaviors
related to increases in dopamine activity, including paw treading, vacuous chewing, and
stereotypic motor movements. Several studies have shown a significant increase in stereotypic
behaviors when the dopamine system is significantly elevated (Szechtman, Sulis, & Eilam, 1998;
Tizabi et al., 2002), and this significant increase in stereotypic activity resulted in an overall
decrease in locomotor activity. Thus, we hypothesize the dopamine system may be further
elevated in D2-primed female adolescents as compared to D2-primed male adolescents, which
could be related to sex differences in dopamine D2 receptor sensitivity in adolescents (Frantz &
Van Hartesveldt, 1999) or possibly related to increases in the dopamine system in response to
psychostimulants in females as compared to males (Becker, 1999). This issue is currently under
investigation in our laboratory, as we have recently collected microdialysis samples from the
nucleus accumbens core of both D2-primed and non D2-primed male and female adolescent rats
that were sensitized to nicotine identical to this study, and those samples will soon be analyzed.
Adult Results
Adult D2-primed females administered saline demonstrated a significant increase in
locomotor sensitization that persisted throughout training, an effect that was not observed in
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adult male animals. This effect again may be related to sex differences in dopamine D2 receptor
function in adults. Interestingly, D2-primed female adult rats administered saline demonstrated a
significant increase in locomotor activity as compared to the first week of training, but this did
not occur in D2-primed male adult rats nor in D2-primed adolescent rats. This appears to indicate
an age and gender difference in the dopamine system that appears to be related to locomotor
activity (Frantz & Van Hartesveldt, 1999; Schindler& Carmona, 2002). The adult female Q-S
group demonstrated an increase in locomotion by week three that was not mimicked in adult
males. The adolescent female Q-S group also showed increased activity as compared to female
controls, but this effect was not as robust as observed in adults. This appears to indicate that an
increase of D2 receptor sensitivity produces a significant increase in activity in females, which is
a different pattern of activity as compared to males. This result is consistent with past findings by
Schindler and Carmona (2002) that have shown increases in locomotor activity in adult female
rats when the D2 receptor is activated as compared to males.
Dopamine D2-primed adult males and females administered nicotine demonstrated more
robust sensitization to nicotine in week 3 of testing as compared to non D2-primed animals
administered saline. Both groups also significantly increased locomotion across weeks. We
hypothesize that this increase in locomotor sensitization is because of the increase in
dopaminergic activity at D2-primed synapses (Nowak et al., 2001, 2002). Additionally, D2primed females showed significantly increased levels of locomotion as compared to males in the
current study. This is consistent with past results by Booze et al. (1999) who showed that
repeated i.v. administration of nicotine to resulted in an overall increase in activity in females as
compared to males. Although there are little data comparing the locomotor effects of nicotine on
males versus females, similar effects are found with administration of the psychostimulant
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cocaine. Cocaine administration caused significant increases in locomotor activity in all animals
with females exhibiting a heightened effect of the drug as compared to males. Females showed a
greater sensitivity to the D1 antagonist SCH 23390, but both groups showed equal sensitivity to
the D2 antagonist eticlopride.
Non D2-primed adults administered nicotine also demonstrated a significant increase in
locomotor activity at week 3 as compared to non D2-primed adults administered saline, with a
more robust increase in sensitization between weeks 1 and 2 as compared to the differences in
activity between weeks 2 and 3. This is consistent with past work by Faraday et al. (2003) that
demonstrated a more robust increase in activity in the first six exposures to nicotine, with activity
levels tapering off over the last six exposures to nicotine. Interestingly, in both past studies and
the current study, a hypoactive response to nicotine was observed in the first exposure to the
drug (Bevins & Palmatier, 2003; Dwoskin et al., 1999; Faraday et al., 2003), an effect that was
seen in both male and female adult animals, but not in D2-primed adolescent male animals.
A Comparison of Adolescent Versus Adult Results
In fact, past studies by Schindler and Carmona (2002) and Frantz and Van Hartesveldt
(1999) have shown a significant sex difference in dopamine D2 sensitivity in adolescent rats.
These studies have shown that male adolescents have a heightened response to quinpirole that
tapers off in adulthood. Contrary to results observed here, Cruz, Delucia, and Planeta (2005)
showed that adult but not adolescent males show locomotor sensitization because of repeated
exposure to nicotine. However, this study used a lower dose of nicotine (.4mg/kg) and a different
route of administration (subcutaneous) than the current study, which may contribute to
contradictory results.
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Proposed Mechanism
We hypothesize that the significant increase in activity as observed in both D2-primed
adolescent and adult rats observed in the present study is because of the action of nicotine at
dopaminergic synapses. Nicotine acts to increase dopamine (DA) release by acting at
presynaptically located nicotinic receptors (nAChRs), which are presynaptically located on
dopaminergic terminals in the nucleus accumbens (Barik & Wonnacott, 2006). When nicotine
binds to the nAChR, calcium enters the cell and binds to the protein complex calmodulin that
carries synaptic vesicles containing dopamine to the cell membrane. Dopamine is then released,
diffuses across the synapse, and binds to primed (indicated by the ‘+’ in Figure 7) dopamine D2
receptors, increasing the overall dopaminergic response in D2-primed rats given nicotine.
Further, it is now known that nicotine blocks the action of dopamine on the presynaptically
located D2 autoreceptor, increasing the dopaminergic response (Barik & Wonnacott, 2006).
Therefore, an increased dopaminergic response to nicotine explains the more robust nicotine
sensitization observed in the present study. However, it is likely, that the D1 receptor is playing
the more important role in locomotor sensitization to nicotine. Essentially, the primed D2
receptors may produce an overall increased dopaminergic response, but the action of dopamine
at D1 receptors is responsible for the increased locomotor sensitization, based on the several
studies that have shown that the D1, and not the D2 receptor, plays a more important role in
sensitization to psychostimulants (Vezina & Stewart, 1989) Additionally, females demonstrate a
significant increased locomotor response because of increases of sensitivity in the dopaminergic
system, and females have shown a significant increase in dopamine release in response to
nicotine as compared to males in a past study (Faraday, O’Donoghue, & Grunberg, 2003).
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Alternative Explanations for This Proposed Mechanism.
Nicotine has been shown to have substantial effects on other neurotransmitters, thus,
there are alternative explanations for the phenomena shown here. For instance, several studies
have shown that pretreatment with glutamatergic NMDA antagonists block nicotine sensitization
(Domino, 2001; Kelsey, Beer, Wagner, et al., 2002; Shoaib, Benwell, Akbar, Stolerman, &
Balfouret, 1994; Shoaib, Schindler, Goldberg, & Pauly, 1997; Shoaib, Shippenberg, Goldberg, &
Schindler, 1995;). Other results have confirmed that glutamate transmission may control
dopamine-dependent locomotor function and synergistically combine with D2 receptor
activation (David et al., 2002). If this is the case, glutamate may be acting on primed D2
receptors ultimately resulting in an increased dopamine response. Relevant to this explanation,
Carlsson et al. (2000) have proposed that glutamate and dopamine functionally antagonize each
other when stimulating the striatal GABA-ergic projection neurons, resulting in overall
depressed neuronal activity. Smoking may counteract this functional antagonism through
increasing the activity of both dopamine and glutamate. Regardless, the majority of the evidence
has shown that nicotine increases dopamine release in the NAcc core through direct agonist
action at nicotinic receptors, and this increased dopamine release plays a primary role in nicotine
locomotor sensitization (Di Chiara et al., 2004; Shim, et al., 2001; Shoaib et al., 1994).
BDNF Results: Adolescents
BDNF analyses revealed that nicotine produces a significant increase in BDNF in the
nucleus accumbens in adolescent females but not adolescent males. Interestingly, neonatal
quinpirole treatment did not produce any significant effect in adolescents. This increase in
BDNF in females actually is consistent with findings that shown increases of BDNF activity in
the nucleus accumbens produces a significant increase in activity (French et al., 1999), and
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several studies have shown overall significant increases in activity in females as compared to
males, and this sex difference is especially prevalent in adolescent females (Durany, 2001;
French et al, 1999). The mechanism by which this occurs is unknown but is presumably because
of the increases in dopamine system that have been shown to be heightened in females after
psychostimulant administration (Becker, 1999).
Another issue here is that brain tissue was taken from these females when they were 50
days of age, and female rats begin estrus cycling around 42 days of age. Thus, these females
have only been cycling for roughly a week when this tissue was taken, and surges in estrogen
may be especially robust at this age, which may have affected our results. As discussed below,
there was not a sex difference observed in adults, so this increase in BDNF produced by nicotine
appears to be an age-related effect.
BDNF Results: Adults
BDNF analyses revealed that neonatal quinpirole treatment produced a significant
decrease in BDNF in the nucleus accumbens that was alleviated by adulthood nicotine treatment.
Interestingly, nicotine treatment alleviated significant decreases in NAcc BDNF of D2-primed
animals, similar to past reports from this laboratory demonstrating that subchronic nicotine
administration alleviates significant decreases of BDNF levels in the hippocampus (Brown et al.
2006). These similar findings may be because of a similar mechanism, or it may indicate a
relationship in dopaminergic activity between these two brain areas. For example, increased
activity in the hippocampus because of amphetamine may be because of modulation of the
hippocampus by the nucleus accumbens (White, Whitaker, & White, 2006) However, recent
research from this laboratory has shown that nicotine treatment produces a significant decrease
in BDNF levels in the hippocampus of non D2-primed adult female animals but not in males
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(Brown et al. 2006). This clearly shows that there may be sex differences in BDNF activity in
response to nicotine that appears to produce differential changes depending on the brain area
analyzed.
One possibility is that dopamine D2-primed adolescent and adult males administered
saline do not show significantly increased locomotor activity over time, possibly because of the
fact that they are deficient in BDNF; however, nicotine increases BDNF, therefore producing an
increased locomotor sensitization response. This effect may be purely correlational, or may be
indicative of a change in neurochemistry rather than a change in behavior related to BDNF.
Conversely, D2-primed adolescent and adult females administered saline both demonstrated
significant increases in activity over days of testing, yet female adults showed decreased levels
of BDNF, and female adolescents showed no change in BDNF levels as compared to control
animals. There were no sex differences in BDNF levels in adults, suggesting that BDNF either is
not related to locomotor activity, or that BDNF plays a role in locomotor sensitization in adult
males but not in adult females. Other studies have shown that BDNF appears to play a role in
locomotor sensitization, but to date, no study has examined the relationship between locomotor
sensitization and BDNF protein levels in rat brain tissue. Interestingly, there has also been no
study to examine sex differences in BDNF levels. Past studies that examined BDNF levels have
found increases in mRNA levels of BDNF in the nucleus accumbens because of nicotine
treatment (Le Foll, Diaz, & Sokoloff, 2005), but this was shown in male rats and female rats
were not analyzed. These results support past findings of increased dopaminergic activity
because of nicotine’s ability to induce locomotor sensitization (Marshall et al., 1997).
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Synaptic Effects of Quinpirole and Nicotine
Nicotine acts to increase dopamine (DA) release by acting at presynaptically located
nicotinic receptors (nAChRs). Dopamine diffuses across the synapse, binding to primed
(indicated by the ‘+’) dopamine D2 receptors, increasing the overall dopaminergic response in
D2-primed rats given nicotine (see Figure 7). Therefore, an increased dopaminergic response to
nicotine explains the more robust nicotine sensitization described in this study. Additionally,
females demonstrate a significant increase in dopamine release in response to nicotine as
compared to males in both past studies (Marshall et al., 1997) and the current study.

Figure 7. Synapse Diagram
Limitations of the Current Study
Although the dose of nicotine used in the current study is clinically relevant to
approximately 14-16 cigarettes per day in humans (Hieda et al., 1999), a dose response curve for
nicotine was not examined. According to the literature, doses of .01 mg/kg and 1.0 mg/kg
nicotine produce drastically different results between adult and adolescent males and may also
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have different effects in adult and adolescent females (Faraday et al., 2003). Because of major
differences in behavioral responses with different doses of nicotine, it may be worthwhile to
examine other doses of nicotine in future studies.
Suggestions for Future Research
The current study examined the locomotor enhancing properties of nicotine using
systemic administration of the drug. However, the use of alternative routes of administration may
give a better understanding of nicotine’s effects on locomotion and brain function. For example,
intracranial administration of the drug may give insight as to brain areas that may be mediating
these effects, as the drug could be applied directly to different brain areas and underlying
mechanisms in these brain areas identified.
The use of microdialysis to investigate the locomotor activating effects of nicotine would
also be pertinent to this study. It is known that nicotine’s agonistic effects on the dopamine
system cause an increase in dopamine release at the terminal. This would be useful because it
would allow us to look at the changes in dopamine release that occur while the animal is under
the influence of nicotine. A study is currently underway in our laboratory to investigate nicotine
and microdialysis.
In past research, others have shown a dose response to the effects of nicotine as well as
quinpirole, which was not examined in this study. Frantz and Van Hartesveldt (1999) showed
differences in age and gender in dose responses to quinpirole, and Faraday et al. (2003) showed
differences in dose response to nicotine in adult and adolescent male animals. However,
methodology (use of neonatal quinpirole treatment versus adulthood quinpirole treatment) may
alter the outcome of a dose response to quinpirole. Methodology would also affect the doseresponse to nicotine that is shown by Faraday et al., who showed a hypoactive response to
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nicotine in adolescent males in response to 0.1 mg/kg and 1.0 mg/kg but not 0.5 mg/kg nicotine
treatment. Our study also did not show a hypoactive response to 0.5 mg/kg nicotine in D2primed adolescent males, suggesting that D2-priming blocks the hypoactive response to nicotine.
D2-priming may also block the hypoactive response to nicotine at different doses.
To date, no study has looked at a dose response to quinpirole and its interaction with
nicotine. The current study showed that neonatal quinpirole treatment blocks the hypoactive
response to nicotine in adolescent males but no other group. By using a dose response with
quinpirole, it is likely that a lower or higher dose may not attenuate the hypoactive response to
nicotine in adolescent males. Additionally, a dose response may show that quinpirole blocks the
hypoactive response to nicotine in females or other pretreatment groups.
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